Form 4: Cogent Biosciences Chief Legal Officer Granted Stock Options

Cogent Biosciences' Chief Legal Officer, Evan Kearns, was granted 230,000 stock options on January 23, 2025, which vest over four years.

Summary

• Evan Kearns, the Chief Legal Officer of Cogent Biosciences, was granted 230,000 stock options on January 23, 2025.
• These options have an exercise price of $8.89 and will vest in equal monthly installments over a four-year period.
• The options expire on January 23, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options to the Chief Legal Officer aligns his interests with the company's long-term success.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

The granting of stock options is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, often used to align management's interests with those of shareholders.
• Vesting schedules, such as the four-year monthly vesting in this case, are also typical to encourage long-term commitment.
• The exercise price of $8.89 would be compared to the current market price of the stock to determine the value of the options.

Stakeholder Impact

• The stock option grant may have a positive impact on shareholders by aligning the Chief Legal Officer's interests with the company's long-term performance.

Key Dates

Keywords

stock options, executive compensation, Cogent Biosciences, Evan Kearns, vesting, equity